**Supplementary Table S1.** Clinical activity for phase 1b cohort

|  |  |
| --- | --- |
| **Parameter** | **Phase 1b****2L+ D20+T1****(*n* = 6)** |
| ORR, *n* (%)Complete responsePartial responseStable diseaseProgressive diseaseNon-evaluableOngoing response rate | 0002 (33.3)3 (50.0)1 (16.7)NA |
| DCR, *n* (%) [95% CI] | 2 (33.3) [4.3–77.7] |
| DCR24, *n* (%) [95% CI] | 1 (16.7) [0.4–64.1] |
| Median time to response, weeks | NA |
| Median duration of response, weeks | NA |

2L+ = received treatment in the second-line (or greater) setting; D = durvalumab; DCR = disease control rate (complete response + partial response + stable disease); DCR24, DCR at 24 weeks (complete response + partial response + stable disease ≥24 weeks); NA = not applicable; ORR = objective response rate; T = tremelimumab.